Furthermore, SETBP1 mutations inhibit protein degradation, and SETBP1 overexpression seems to facilitate leukemic transformation in ASXL1 mutated MDS through inhibition of PP2A activity and thereby AKT activation, repressed TGFβ, increased HOXA gene expression and induction of a molecular stem cell signature [143]. Here, SETBP1 is linked to myelodysplastic syndrome.